Magnifying LeNS Archives - Page 7 of 7

The Magnifying LeNS highlights the latest in the lung cancer treatment landscape as seen by GO2 for Lung Cancer’s Science and Research team. Explore our full-format newsletter archive or sign up to receive the Magnifying LeNS.

Treatment Insights for KRAS Mutated Non-Small Cell Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2021-06-04T08:36:15-05:00April 13th, 2021|Magnifying LeNS, Newsletter Articles, Science and Research|

By Daniel A. Saez, MSc, Treatment and Trials Navigator, GO2 for Lung Cancer Rebecca (KRAS driven stage 4 NSCLC patient) and Wayne Yeung (caregiver) Since the original publication of this article, the United States Food [...]

Learning About Everyone: The Importance of Advancing Inclusive Research

Bethany Johnson (GO2 for Lung Cancer)2023-05-02T14:32:37-05:00January 14th, 2021|Magnifying LeNS, Science and Research|

By Jennifer C. King, Ph.D., Chief Scientific Officer, GO2 for Lung Cancer Are scientists learning enough about how people just like you respond to new treatments? You may be surprised. Clinical trial participation rates among people with cancer in the [...]

Lung Cancer Registry: Partnering with Patients and Caregivers to Drive Research Forward

Bethany Johnson (GO2 for Lung Cancer)2024-02-21T10:28:52-06:00January 14th, 2021|Magnifying LeNS, Science and Research|

By Jacinta R. Wiens, Ph.D., M.S., Director, Lung Cancer Registry, GO2 for Lung Cancer The Lung Cancer Registry (LCR), created by the GO2 for Lung Cancer, is a global online database that was launched in 2016. The LCR was designed [...]

When Worlds Collide: Research at the Intersection of COVID-19 and Lung Cancer

Bethany Johnson (GO2 for Lung Cancer)2021-03-12T15:01:44-06:00January 14th, 2021|Magnifying LeNS, Science and Research|

By Amy C. Moore, Ph.D., Director, Science & Research, GO2 for Lung Cancer 2020 started off on a high note – we were celebrating the largest single year drop in cancer mortality. Then COVID-19 showed up and the cancer [...]

How Biomarker Testing Affects Patients

Bethany Johnson (GO2 for Lung Cancer)2021-03-12T15:01:45-06:00January 14th, 2021|Magnifying LeNS, Science and Research|

By Daniel A. Saez, M.Sc., Treatment and Trials Navigator, GO2 for Lung Cancer In today’s lung cancer care landscape, biomarker testing has become a crucial part of the treatment decision for many oncologists. Targeted therapies can be more effective [...]

Trends in Treatment of EGFR+ NSCLC after Progression Following Tagrisso Treatment

Bethany Johnson (GO2 for Lung Cancer)2023-06-14T12:16:57-05:00January 14th, 2021|Magnifying LeNS, Science and Research|

By Andrew Ciupek, Ph.D., Manager, Clinical Research, GO2 for Lung Cancer Approximately 30% of Non-Small Cell Lung Cancers (NSCLC) have an EGFR mutation. For these patients EGFR targeted therapy has greatly increased survival. Tagrisso (osimertinib) has become the drug [...]